Previous 10 | Next 10 |
LONDON and NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and for neuropathic corneal pain, a severe ...
LONDON and NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and for neuropathic corneal pain, a severe ...
2023-10-31 13:18:43 ET More on OKYO Pharma OKYO shares retreat 12% after rallying ahead of Phase 2 study update OKYO Pharma announces capital raise of $3.95M without any underwriter or agent Financial information for OKYO Pharma For further details see: O...
Pricing of a registered direct offering for $1.64M of 1,092,600 ordinary shares at an offering price of $1.50 per ordinary share Simultaneous extinguishment of $4.20M of payables by issuing 2,766,667 ordinary shares, at the offering price of $1.50 per ordinary share, m...
OKYO plans to initiate a 40-patient OK-101 open-label clinical trial in Q1 2024 with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients with NCP. Second clinical indication for OK-101 which is currently in 240-patient Phase 2 clini...
2023-10-06 08:53:38 ET OMNIQ ( OMQS ) -44% announces pricing of public offering. Wheeler Real Estate Investment Trust ( WHLR ) -21% . ShiftPixy ( PIXY ) -19% . Nanobiotix ( NBTX ) -15% . Aehr Test ( AEHR ) -11% . ...
2023-10-05 11:53:30 ET More on OKYO Pharma OKYO Pharma announces capital raise of $3.95M without any underwriter or agent OKYO Pharma rebounds on withdrawal of equity offering Financial information for OKYO Pharma For further details see: OKYO shares retr...
Over 95% of randomized DED patients have completed 4 weeks of dosing in the planned 12-week Phase 2 trial, with 72% of randomized DED patients completing 8 weeks, and 7.1% of patients completing the entire 12-week trial. The dropout rate is 5.4% and unrelated to side effects. Top-...
2023-09-15 08:14:04 ET More on pre-market losers stock: Compare metrics for AXLA to HNST, SLE Honest Company: Honestly Bad Economics The Honest Company: Very Few Options The Honest Company, Inc. ( HNST ) Q2 2023 Earnings Call Transcript The Honest...
LONDON and NEW YORK, Sept. 15, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED”), today announced the clos...
News, Short Squeeze, Breakout and More Instantly...
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024 OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain ...
Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease (DED) trial Conjunctival staining and ocular pain represe...
--News Direct-- OKYO Pharma Ltd CEO Gary Jacobs joined Steve Darling from Proactive to share additional key findings from the Phase 2 clinical trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED). This trial involved 240 pat...